Recently, clinical trials of tirzepatide, a dual GLP-1R and glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist, have achieved approximately 20% weight loss in substantial proportions of people with obesity (1). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.